|
Study | Population | Study type (data source) | AKI (WRF) definition | Incidence AKI (%) | Cardiac disease | Outcome |
|
Nohria et al., 2008 [15] | n = 433 Mean Age 56 yrs Male % DM 34% HTN 47% | Retrospective (ESCAPE Trial) | SCr > 26.5 μmol/L | 29.5 | Hospitalized ADHF | All-cause death (6 m) (HR) increased for SCr > 106.1 AKI (>26.5 μmol/L) not associated with death/readmission |
Logeart et al., 2008 [16] | n = 416 Age 71 yrs Male 59% DM 23% HTN 42% | Prospective | SCr > 26.5 μmol/L | 37 | Hospitalized ADHF Prevalence: LVEF 0.35 LVEF ≤ 0.45 70% Prior HF 45% Prior MI 55% | All-cause death (6 m) or Readmission (adj-HR) 1.74 Increased LOS 3 d Risk persisted whether AKI transient or not |
Metra et al., 2008 [17] | n = 318 Mean Age 68 yrs Male 60% DM 34% HTN 53% | Prospective | SCr > 26.5 μmol/L & ≥ 25% | 34 | Hospitalized ADHF Prevalence: Prior MI 51% Prior HF 58% | CV death or readmission (adj-HR) 1.47 Increased LOS 7 d |
Aronson and Burger [18] | n = 467 | Prospective | SCr > 44.2 μmol/L | 33.9 Transient 7.9 Persistent 14.3 | Hospitalized ADHF | All-cause death (6 m) 17.3%, 20.5%, and 46.1% for no WRF, transient WRF, persistent WRF Adj-HR for persistent WRF 3.2 (95% CI, 2,1–5.0) |
Belziti et al., 2010 [19] | n = 200 | Retrospective | SCr > 26.5 μmol/L & ≥ 25% | 23 | Hospitalized ADHF | Higher mortality at 1-year (P < .01) Rehospitalization for WRF (HR 1.65, P = .003) Longer median LOS for WRF (9 versus 4 days, P < .05) |
Kociol et al., 2010 [20] | n = 20,063 | Retrospective | SCr > 26.5 μmol/L | 17.8 | Hospitalized ADHF | 1-year mortality 35.4% (HR 1.12, 95% CI, 1.4–1.20) Rehospitalization 64.5% |
|